Kura Oncology to Participate in JMP Securities Hematology and Oncology Summit
Kura Oncology to Participate in JMP Securities Hematology and Oncology Summit
Kura Oncology is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. The Company's pipeline consists of small molecule drug candidates that target cancer signaling pathways. Ziftomenib, a once-daily, oral menin inhibitor, is the first and only investigational therapy to receive Breakthrough Therapy Designation from the U.S. Food and Drug Administration for the treatment of relapsed/refractory (R/R) NPM1-mutant acute myeloid leukemia (AML). In November 2024, Kura entered a global strategic collaboration agreement with Kyowa Kirin Co., Ltd. to develop and commercialize ziftomenib for AML and other hematologic malignancies. Enrollment in a Phase 2 registration-directed trial of ziftomenib in R/R NPM1-mutant AML has been completed and the companies anticipate submission of a New Drug Application in 2025. Kura is also conducting a series of clinical trials to evaluate ziftomenib in combination with current standards of care in newly diagnosed and R/R NPM1-mutant and KMT2A-rearranged AML. KO-2806, a next-generation farnesyl transferase inhibitor, is being evaluating in a Phase 1 dose-escalation trial as a monotherapy and in combination with targeted therapies. Tipifarnib, a potent and selective FTI, is currently in a Phase 1/2 trial in combination with alpelisib for patients with PIK3CA-dependent head and neck squamous cell carcinoma. For additional information, please visit Kura's website at and follow us on X and LinkedIn.SAN DIEGO, Nov. 25, 2024 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced its participation in the upcoming JMP Securities Hematology and Oncology Summit. Troy Wilson, Ph.D., J.D., President and Chief Executive Officer, is scheduled to participate in a virtual fireside chat at 2:00 p.m. ET / 11:00 a.m. PT on December 2, 2024.
聖地亞哥，2024年11月25日（GLOBE NEWSWIRE）——致力於實現精準藥物治療癌症承諾的臨床階段生物製藥公司庫拉腫瘤學公司（納斯達克股票代碼：KURA）今天宣佈參加即將舉行的JMP Securities血液學和腫瘤學峯會。總裁兼首席執行官特洛伊·威爾遜博士、法學博士計劃於美國東部時間下午 2:00 /太平洋時間上午 11:00 參加虛擬爐邊談話。
A live audio webcast of the fireside chat will be available in the Investors section of Kura's website at , with an archived replay available following the live event.
爐邊談話的網絡直播將在庫拉網站的 「投資者」 部分播出，活動結束後將提供存檔重播。
About Kura Oncology
關於庫拉腫瘤學
Kura Oncology is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. The Company's pipeline consists of small molecule drug candidates that target cancer signaling pathways. Ziftomenib, a once-daily, oral menin inhibitor, is the first and only investigational therapy to receive Breakthrough Therapy Designation from the U.S. Food and Drug Administration for the treatment of relapsed/refractory (R/R) NPM1-mutant acute myeloid leukemia (AML). In November 2024, Kura entered a global strategic collaboration agreement with Kyowa Kirin Co., Ltd. to develop and commercialize ziftomenib for AML and other hematologic malignancies. Enrollment in a Phase 2 registration-directed trial of ziftomenib in R/R NPM1-mutant AML has been completed and the companies anticipate submission of a New Drug Application in 2025. Kura is also conducting a series of clinical trials to evaluate ziftomenib in combination with current standards of care in newly diagnosed and R/R NPM1-mutant and KMT2A-rearranged AML. KO-2806, a next-generation farnesyl transferase inhibitor, is being evaluating in a Phase 1 dose-escalation trial as a monotherapy and in combination with targeted therapies. Tipifarnib, a potent and selective FTI, is currently in a Phase 1/2 trial in combination with alpelisib for patients with PIK3CA-dependent head and neck squamous cell carcinoma. For additional information, please visit Kura's website at and follow us on X and LinkedIn.
Kura Oncology是一家臨床階段的生物製藥公司，致力於實現治療癌症的精準藥物的承諾。該公司的產品線包括靶向癌症信號通路的小分子候選藥物。Ziftomenib是一種每日一次的口服腦膜蛋白抑制劑，是第一種也是唯一一種獲得美國食品藥品監督管理局突破性療法稱號的研究性療法，用於治療復發/難治性（R/R）NPM1突變體急性髓系白血病（AML）。2024年11月，庫拉與協和麒麟株式會社簽訂了全球戰略合作協議，以開發和商業化治療急性髓細胞白血病和其他血液系統惡性腫瘤的齊夫託美尼。齊夫託美尼在R/R npm1突變體急性髓細胞白血病中進行的一項以註冊爲導向的2期試驗的註冊已經完成，兩家公司預計將在2025年提交新藥申請。庫拉還正在進行一系列臨床試驗，以評估齊夫託美尼與新診斷和復發/難治性NPM1突變體和KMT2A重新排列的急性髓細胞白血病的當前護理標準相結合。KO-2806 是下一代法尼酰轉移酶抑制劑，正在作爲單一療法和靶向療法聯合使用的 1 期劑量遞增試驗中進行評估。Tipifarnib是一種強效的選擇性FTI，目前正在與阿培利西布聯合進行1/2期試驗，用於治療依賴PIK3CA的頭頸部鱗狀細胞癌患者。欲了解更多信息，請訪問庫拉的網站，並在 X 和 LinkedIn 上關注我們。
Kura Contacts
庫拉聯繫人
Investors:
Pete De Spain
Executive Vice President, Investor Relations &
Corporate Communications
(858) 500-8833
pete@kuraoncology.com
投資者：
彼得·德·西班牙
投資者關係與執行副總裁
企業傳播
(858) 500-8833
pete@kuraoncology.com
Media:
Cassidy McClain
Vice President
Inizio Evoke Comms
(619) 849-6009
cassidy.mcclain@inizioevoke.com
媒體：
卡西迪·麥克萊恩
副總統
Inizio Evoke Comms
(619) 849-6009
cassidy.mcclain@inizioevoke.com
